Nimenrix

Indicated For

invasive meningococcal disease

About This Medication

# Pfizer Patient Assistance Program Guide: How to Get Nimenrix at Low or No Cost ## About This Program The **Pfizer Patient Assistance Program** is a joint initiative of Pfizer Inc. and the Pfizer Patient Assistance Foundation that has helped U.S. patients access Pfizer medications for more than 30 years. This program provides eligible patients with free or significantly discounted Pfizer medicines, including vaccines like Nimenrix (meningococcal group A, C, W-135, and Y conjugate vaccine). In 2024 alone, the program provided over 351,000 Pfizer prescriptions to 44,000 patients at no cost. ## About Nimenrix Nimenrix is a meningococcal conjugate vaccine manufactured by Pfizer that protects against meningococcal disease caused by serogroups A, C, W-135, and Y. This vaccine is important for preventing serious bacterial infections that can cause meningitis and septicemia. Your healthcare provider may recommend Nimenrix based on your age, health status, and risk factors for meningococcal disease. ## Who Qualifies for Assistance To be eligible for the Pfizer Patient Assistance Program for Nimenrix, you must meet ALL of the following criteria: - **U.S. Residency**: Be a resident of the United States or an applicable U.S. territory - **Valid Prescription**: Have a valid prescription written by a healthcare provider licensed in the U.S. or applicable U.S. territory - **Outpatient Setting**: Be treated in an outpatient setting of care - **FDA-Approved Indication**: Have an FDA-approved diagnosis for Nimenrix - **Financial Need**: Demonstrate an inability to afford your prescription costs - **Insurance Status**: Be uninsured or have government insurance (such as Medicare or Medicaid). Commercially insured patients are generally not eligible for free medication through this program, though they may qualify for co-pay assistance programs - **Income Eligibility**: Meet the program's income requirements (see Income Eligibility section below) ## Income Eligibility Requirements Your annual household pre-tax income cannot exceed **300% of the Federal Poverty Level (FPL)**, adjusted for household size. This threshold applies to Nimenrix as a primary care vaccine product. ### 2026 Income Limits (300% FPL) | Household Size | Maximum Annual Income | |---|---| | 1 person | $41,820 | | 2 people | $56,460 | | 3 people | $71,100 | | 4 people | $85,740 | | 5 people | $100,380 | | 6 people | $114,900 | | 7 people | $129,540 | | 8 people | $144,180 | *Note: Add $14,640 for each additional household member beyond 8 people.* These income limits are based on the Federal Poverty Level and are subject to change annually. If your household income exceeds these limits, you may not qualify for free medication through this program. ## Insurance Requirements **Uninsured and Government-Insured Patients**: You are eligible if you have no health insurance or only government insurance (Medicare, Medicaid, Veterans benefits, etc.). **Commercially Insured Patients**: If you have private commercial insurance, you are **not eligible** for free medication through the Pfizer Patient Assistance Program. However, you may have other options: - Contact your insurance company about co-pay assistance - Ask your healthcare provider about alternative vaccines or payment plans - Visit GoodRx.com to search for discount coupons on Pfizer medications **Medicare Part D Patients**: If you have Medicare Part D or Medicare Advantage coverage, you must first enroll in the voluntary **Medicare Prescription Payment Plan** before you can be considered for the Pfizer Patient Assistance Program. You can enroll in this plan during Medicare Open Enrollment (beginning October 15 each year) or at any time during the plan year. Contact your prescription health insurance plan or visit www.medicare.gov/prescription-payment-plan for enrollment information. ## Step-by-Step Application Process ### Step 1: Gather Required Documents Before applying, collect the following documents: - Your valid prescription for Nimenrix from your healthcare provider - Proof of income (choose one): - Recent W2 form - Current paycheck stub - Prior year's tax return - Other income documentation - Proof of U.S. residency - Insurance information (if applicable) ### Step 2: Work with Your Healthcare Provider Contact your physician's office or pharmacy to: - Confirm that Nimenrix is available through the Pfizer Patient Assistance Program - Understand your co-payment and total prescription costs - Obtain any required prior authorization from your insurance company (if applicable) - Complete the enrollment form with your healthcare provider's assistance ### Step 3: Submit Your Application You have two options for applying: **Option A: Online Enrollment (Pfizer PAP Connect)** For certain primary care medications, you can apply online at www.PfizerPAPConnect.com. This streamlined process allows eligible patients and healthcare providers to start and complete enrollment online. **Option B: Traditional Application** Submit a completed enrollment form along with your proof of income documentation through your healthcare provider's office or pharmacy. ### Step 4: Consult with a Pfizer Medicine Access Counselor If you have questions or need assistance with the application process, call the toll-free number **1-844-989-PATH (7284)** to speak with a Pfizer Medicine Access Counselor. They can answer your questions and help guide you through the process. ## Timeline and Delivery While the search results do not specify an exact processing timeline, the Pfizer Patient Assistance Program typically processes applications within 1-2 weeks of receiving complete documentation. Once approved, your medication can be delivered to your doctor's office or directly to your home, depending on the program option selected. Your healthcare provider will be notified of your enrollment status, and they will coordinate with you regarding medication delivery and administration. ## What Happens If Your Application Is Denied If your application for the Pfizer Patient Assistance Program is denied, you have several alternatives: 1. **Review Denial Reason**: Contact the program at 1-844-989-PATH (7284) to understand why your application was denied. Common reasons include exceeding income limits or having commercial insurance. 2. **Explore Other Assistance Options**: - Ask your healthcare provider about alternative vaccines or manufacturers - Contact your state or local health department about vaccine programs - Inquire about community health center programs that may offer vaccines at reduced cost - Check if you qualify for other Pfizer assistance programs 3. **Use Discount Programs**: Visit GoodRx.com to search for discount coupons on Pfizer vaccines that you can use at participating pharmacies. 4. **Reapply**: If your financial situation changes or you believe there was an error in your application, you may reapply to the program. ## Reauthorization and Refills The Pfizer Patient Assistance Program requires periodic reauthorization to ensure you continue to meet eligibility requirements. Your healthcare provider will notify you when reauthorization is needed. You can request refills for your PAP medications through the online Pfizer PAP Connect tool or by contacting your healthcare provider's office. ## Important Disclaimer This guide provides general information about the Pfizer Patient Assistance Program for Nimenrix. Eligibility requirements, income limits, and program terms are subject to change at any time. The support provided through this program is not contingent on any future purchase of Pfizer products. For the most current and complete information about eligibility, requirements, and terms and conditions, visit www.PfizerRxPathways.com or call 1-844-989-PATH (7284). Your healthcare provider can also provide specific guidance about your eligibility and the application process. This program is designed to help patients in financial need access their medications. If you believe you qualify, we encourage you to apply or contact a Pfizer Medicine Access Counselor for assistance.

Program information last verified: March 30, 2026